Organisation paid for research Program year 2025 Source: CMS Open Payments

Vitreo Retinal Associates

Neither a doctor nor a teaching hospital

Research payments

$65,472

10 payments

Through program year 2025, Vitreo Retinal Associates is reported as receiving $65,472 in research payments, across 10 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$53,853	2
2022	Research	$256	1
2021	Research	$601	2
2020	Research	$3,779	2
2019	Research	$6,982	3

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $65,472 10 payments

Studies the money was for Research payments · program years 2019–2025

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study $53,853 2 payments
A 64-Week, Phase 3B, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6Mg Compared to Aflibercept 2Mg in A Treat to Control Regimen in Patients With Neovascular Age-Related MacUlar Degeneration $5,525 4 payments
A 96-Week, Two-Arm, Randomized, Single-Masked, Multi-Center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 MG Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy $3,155 2 payments
A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic MacUlar Edema $2,465 1 payment
An Open-Label, Single Arm, Multiple Dose Study to Investigate Safety, Pharmacokinetics and Immunogenicity of New Formulation of Rth258 in Pre-Treated Patients With Neovascular Age-Related MacUlar Degeneration $473 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.